Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $24.
Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $24.